ULTRAGENYX PHARMACEUTICAL INC.

(RARE)
  Report
Delayed Nasdaq  -  05/17 04:00:00 pm EDT
54.35 USD   -1.65%
05/17Ultragenyx Pharmaceutical Licenses Abeona Therapeutics' Sanfilippo Syndrome Type A Therapy
MT
05/17ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
05/17Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
GL
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Ultragenyx Commences Dosing in Phase 1/2 Study of UX053 in Glycogen Storage Disease Type III

12/01/2021 | 10:52am EDT


ę MT Newswires 2021
All news about ULTRAGENYX PHARMACEUTICAL INC.
05/17Ultragenyx Pharmaceutical Licenses Abeona Therapeutics' Sanfilippo Syndrome Type A Ther..
MT
05/17ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits (form 8-K..
AQ
05/17Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome T..
GL
05/17Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome T..
AQ
05/10TRANSCRIPT : Ultragenyx Pharmaceutical Inc. Presents at Bank of America 2022 Healthcare Co..
CI
05/10Citigroup Adjusts Price Target on Ultragenyx Pharmaceutical to $146 From $150, Reiterat..
MT
05/09Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell The..
GL
05/09Ultragenyx Announces Upcoming Data Presentations at American Society of Gene & Cell The..
AQ
05/06SECTOR UPDATE : Health Care Stocks Recover Losses on Late Friday
MT
05/06SECTOR UPDATE : Health Care
MT
More news
Analyst Recommendations on ULTRAGENYX PHARMACEUTICAL INC.
More recommendations
Financials (USD)
Sales 2022 373 M - -
Net income 2022 -513 M - -
Net cash 2022 495 M - -
P/E ratio 2022 -7,45x
Yield 2022 -
Capitalization 3 801 M 3 801 M -
EV / Sales 2022 8,86x
EV / Sales 2023 6,93x
Nbr of Employees 1 119
Free-Float 95,6%
Chart ULTRAGENYX PHARMACEUTICAL INC.
Duration : Period :
Ultragenyx Pharmaceutical Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 54,35 $
Average target price 130,06 $
Spread / Average Target 139%
EPS Revisions
Managers and Directors
Emil D. Kakkis President, Chief Executive Officer & Director
Mardi C. Dier Chief Financial Officer & Executive Vice President
Daniel G. Welch Non-Executive Chairman
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Camille L. Bedrosian Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
ULTRAGENYX PHARMACEUTICAL INC.-35.37%3 801
GILEAD SCIENCES, INC.-12.99%79 248
REGENERON PHARMACEUTICALS, INC.5.71%71 927
VERTEX PHARMACEUTICALS19.24%66 967
WUXI APPTEC CO., LTD.-16.20%42 682
BIONTECH SE-38.01%38 834